MedCity News
Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors
The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.
Shares0
FDA approval of cell therapies made from a patient’s own immune cells provided another treatment option for the most serious cases of blood cancer. But this type of treatment, called CAR-T therapy, is cumbersome to manufacture and still hasn’t proven effective in solid tumors.
A different type of cell therapy called tumor infiltrating lymphocytes (TIL) could offer yet another alternative, plus the potential to address solid tumors. Several biotechs have TILs in clinical development. Achilles Therapeutics aims to best them all.
Pork may return to the menu in Congress. Will Texas partake?
Texas Tribune
Tags:
WASHINGTON – Members of the House depart after the first session of the 117th Congress in the House Chamber at the U.S. Capitol in Washington, DC, Jan. 3, 2021.
Credit: Tasos Katopodis/Pool via REUTERS
Sign up for The Brief, our daily newsletter that keeps readers up to speed on the most essential Texas news.
Detractors call them “pork,” invoking the cliche of a local congressman bringing home the bacon. Advocates call them “community project funding.”
Whatever the appellation, the debate over whether Congress can ethically bring back earmarks a maligned spending practice banished a decade ago is fueling debate among Texans in Congress. For some members, earmarks bring to mind an ugly past that landed one of their own in prison. Others see reviving the practice as one way to return to a functional, maybe even bipartisan, political system.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Members of the House depart after the first session of the 117th Congress in the House Chamber at the U.S. Capitol in Washington, DC, Jan. 3, 2021. Credit: Tasos Katopodis/Pool via REUTERS
Sign up for The Brief, our daily newsletter that keeps readers up to speed on the most essential Texas news.
WASHINGTON - Detractors call them “pork,” invoking the cliche of a local congressman bringing home the bacon. Advocates call them “community project funding.”
Whatever the appellation, the debate over whether Congress can ethically bring back earmarks a maligned spending practice banished a decade ago is fueling debate among Texans in Congress. For some members, earmarks bring to mind an ugly past that landed one of their own in prison. Others see reviving the practice as one way to return to a functional, maybe even bipartisan, political system.
MedCity News
J.P. Morgan’s life sciences outlook for 2021
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
Shares0
Source: J.P. Morgan
To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, notes that investment in life sciences reached record-high levels across almost every category and subsector despite unprecedented business challenges. Here are a few of the highlights: